Nivolumab After Surgery and Chemotherapy in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer (An ALCHEMIST Treatment Trial)

Brief summary (registry, in English)

This phase III ALCHEMIST treatment trial studies how well nivolumab after surgery and chemotherapy work in treating patients with stage IB-IIIA non-small cell lung cancer. Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.

What you commit to

• Study type: Interventional · Phase 3
• Planned participants: 903
• From 22 Jul 2016 to the primary completion date, 31 May 2027
• 884 sites in 1 country
• Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Who the study is looking for

Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers

Full criteria on ClinicalTrials.gov

Sites (884)

Sites in registry order. Save your city in your profile to sort them by distance.

Related publications

• Adjuvant Nivolumab vs Observation in Resected Non-Small Cell Lung Cancer: A Randomized Clinical Trial.JAMA · 2026 · PMID 42224490
• Updates on the Perioperative Management of Resectable Non-Small Cell Lung Cancer.J Natl Compr Canc Netw · 2026 · PMID 41911908